/PRNewswire/ Centene Corporation (NYSE: CNC) today will host its investor day to outline its 2023 financial guidance as well as provide updates on its.
Centene Corporation has announced it has signed a definitive agreement to sell Magellan Specialty Health to Evolent Health. Centene said it expects to receive over $750 million in aggregate proceeds, including potential earnout. It expects to receive approximately $600 million in proceeds at closing, with at least $400 million paid in cash and the remainder paid in Evolent